JP2021519061A5 - - Google Patents
Info
- Publication number
- JP2021519061A5 JP2021519061A5 JP2020551264A JP2020551264A JP2021519061A5 JP 2021519061 A5 JP2021519061 A5 JP 2021519061A5 JP 2020551264 A JP2020551264 A JP 2020551264A JP 2020551264 A JP2020551264 A JP 2020551264A JP 2021519061 A5 JP2021519061 A5 JP 2021519061A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- induced
- cell
- genome
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024181460A JP2025013853A (ja) | 2018-03-29 | 2024-10-17 | 操作された免疫エフェクター細胞およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649781P | 2018-03-29 | 2018-03-29 | |
| US62/649,781 | 2018-03-29 | ||
| US201862774052P | 2018-11-30 | 2018-11-30 | |
| US62/774,052 | 2018-11-30 | ||
| USPCT/US2018/067289 | 2018-12-21 | ||
| PCT/US2018/067289 WO2019126748A1 (en) | 2017-12-22 | 2018-12-21 | Enhanced immune effector cells and use thereof |
| PCT/US2019/024686 WO2019191495A1 (en) | 2018-03-29 | 2019-03-28 | Engineered immune effector cells and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024181460A Division JP2025013853A (ja) | 2018-03-29 | 2024-10-17 | 操作された免疫エフェクター細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519061A JP2021519061A (ja) | 2021-08-10 |
| JP2021519061A5 true JP2021519061A5 (cg-RX-API-DMAC10.html) | 2022-04-04 |
| JP7575271B2 JP7575271B2 (ja) | 2024-10-29 |
Family
ID=68060556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551264A Active JP7575271B2 (ja) | 2018-03-29 | 2019-03-28 | 操作された免疫エフェクター細胞およびその使用 |
| JP2024181460A Pending JP2025013853A (ja) | 2018-03-29 | 2024-10-17 | 操作された免疫エフェクター細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024181460A Pending JP2025013853A (ja) | 2018-03-29 | 2024-10-17 | 操作された免疫エフェクター細胞およびその使用 |
Country Status (13)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178933A2 (en) | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| CN110628821B (zh) * | 2018-06-25 | 2022-02-18 | 首都医科大学宣武医院 | 一种细胞模型及其制备方法、应用 |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| BR112021021608A2 (pt) * | 2019-04-30 | 2021-12-21 | Atara Biotherapeutics Inc | Células car-t direcionadas a cd19 específicas para antígeno |
| JP7728747B2 (ja) * | 2019-08-23 | 2025-08-25 | サナ バイオテクノロジー,インコーポレイテッド | Cd24発現細胞およびそれらの用途 |
| EP4041759A4 (en) * | 2019-10-07 | 2023-12-20 | Fate Therapeutics, Inc. | IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTIVE CELL ENGINEERING AND ITS USE |
| EP4045539A4 (en) * | 2019-10-17 | 2024-03-13 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| CA3179969A1 (en) * | 2020-04-09 | 2021-10-14 | Wallkill BioPharma, Inc. | Treating autoimmune diseases with genetically modified cells |
| CA3182286A1 (en) * | 2020-05-04 | 2021-11-11 | Editas Medicine, Inc. | Selection by essential-gene knock-in |
| KR20230040337A (ko) * | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| WO2022056489A1 (en) * | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
| CN114457025A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达btla阻断物的多能干细胞或其衍生物及应用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| CN114591950A (zh) * | 2020-12-04 | 2022-06-07 | 武汉友芝友生物制药股份有限公司 | 敲除cd38基因的细胞系、其构建方法及应用 |
| CN114107211B (zh) * | 2020-12-04 | 2025-09-30 | 未来智人再生医学研究院(广州)有限公司 | 一种多能干细胞及其衍生物 |
| CN114645018A (zh) * | 2020-12-18 | 2022-06-21 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| CN114657137A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| CN114657133A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向IL-4 Rα的shRNA和/或shRNA-miR的多能干细胞 |
| KR20230155521A (ko) | 2021-03-11 | 2023-11-10 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| US20240254444A1 (en) * | 2021-05-04 | 2024-08-01 | Shoreline Biosciences, Inc. | Engineered cells for therapy |
| MX2023014356A (es) * | 2021-06-02 | 2024-02-15 | Metagenomi Inc | Sistemas crispr de clase ii, tipo v. |
| KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
| US20240307540A1 (en) * | 2021-07-02 | 2024-09-19 | Fate Therapeutics, Inc. | Protected effector cells and use thereof for allogeneic adoptive cell therapies |
| CN113278652B (zh) * | 2021-07-20 | 2021-10-01 | 卡瑞济(北京)生命科技有限公司 | 增加Survivin表达的CAR-T细胞并联合IL-15在制备抗肿瘤药物中的应用 |
| CN122483217A (zh) * | 2021-08-06 | 2026-07-31 | 上海驯鹿生物技术有限公司 | 靶向cd7的嵌合抗原受体及其应用 |
| CA3228865A1 (en) * | 2021-08-18 | 2023-02-23 | Bahram Valamehr | Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody |
| CN116103239A (zh) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| WO2023093763A1 (en) * | 2021-11-24 | 2023-06-01 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for cell-based immunotherapies cross-reference |
| WO2023116929A1 (en) * | 2021-12-24 | 2023-06-29 | Hemacell Therapeutics Inc. | Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination |
| CN116804185A (zh) * | 2022-03-25 | 2023-09-26 | 士泽生物医药(苏州)有限公司 | 一种通用型细胞及其制备方法 |
| KR20250004622A (ko) | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
| KR20250005097A (ko) | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| CN116948012B (zh) * | 2022-04-13 | 2024-07-26 | 星奕昂(上海)生物科技有限公司 | 增强细胞功能的cd16抗剪切突变体 |
| CA3252595A1 (en) | 2022-05-25 | 2023-11-30 | Metagenomi Therapeutics, Inc. | LIVER ENZYME EXPRESSION SUPPLEMENTATION |
| CN116716342A (zh) * | 2022-06-22 | 2023-09-08 | 南京艾尔普再生医学科技有限公司 | 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物 |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| CN120359048A (zh) * | 2022-09-02 | 2025-07-22 | 美洛德生物医药公司 | 用于细胞特异性表达的组合物及其用途 |
| GB2639327A (en) * | 2022-09-22 | 2025-09-24 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2024102704A2 (en) * | 2022-11-07 | 2024-05-16 | Fate Therapeutics, Inc. | Ipsc-derived nk cell targeting mica/b for solid tumor treatment |
| WO2024183750A1 (en) * | 2023-03-07 | 2024-09-12 | Qihan Hong Kong Limited | A novel immune cell and use thereof for treating diseases |
| WO2024211852A1 (en) * | 2023-04-07 | 2024-10-10 | Fate Therapeutics, Inc. | Ipsc-derived nk cell for lymphoma treatment |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| KR20260024373A (ko) * | 2023-05-05 | 2026-02-20 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 다중-수용체 자연 살해 세포 |
| CN116286905B (zh) * | 2023-05-11 | 2023-08-15 | 内蒙古大学 | 牛源化CRISPR/boCas9基因编辑系统、方法及应用 |
| WO2025031500A1 (zh) * | 2023-08-10 | 2025-02-13 | 深圳市三启生物技术有限公司 | 含有gprc5d抗体的嵌合抗原受体及其应用 |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
| WO2025102504A1 (zh) * | 2023-11-15 | 2025-05-22 | 复旦大学 | 基于i型内含子的环状rna制备方法及其应用 |
| WO2025240349A2 (en) * | 2024-05-15 | 2025-11-20 | Be Biopharma, Inc. | Allogeneic cell compositions and methods thereof |
| WO2025257119A1 (en) * | 2024-06-10 | 2025-12-18 | Repairon Immuno Gmbh | Method of producing a modified immune cell from a pluripotent stem cell (psc) |
| CN119264271B (zh) * | 2024-10-08 | 2025-05-09 | 北京市神经外科研究所 | 一种nk细胞特异性的嵌合抗原受体及其应用 |
| CN121159717B (zh) * | 2025-09-11 | 2026-04-21 | 中邦干细胞科技有限公司 | 一种嵌合蛋白、工程化nk细胞及其制备方法和用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5766944A (en) * | 1996-12-31 | 1998-06-16 | Ruiz; Margaret Eileen | T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| DK3105317T3 (en) * | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| CN113699159A (zh) | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
| US10738278B2 (en) * | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| CA2994746A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| CA3007473A1 (en) | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| JP7653759B2 (ja) * | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| BR112020011017A2 (pt) * | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
-
2019
- 2019-03-28 AU AU2019243315A patent/AU2019243315A1/en not_active Abandoned
- 2019-03-28 KR KR1020207029206A patent/KR102817092B1/ko active Active
- 2019-03-28 BR BR112020019205-8A patent/BR112020019205A2/pt unknown
- 2019-03-28 IL IL277611A patent/IL277611B1/en unknown
- 2019-03-28 US US17/040,951 patent/US20210024959A1/en active Pending
- 2019-03-28 CN CN201980021676.XA patent/CN111954715A/zh active Pending
- 2019-03-28 SG SG11202008977UA patent/SG11202008977UA/en unknown
- 2019-03-28 EP EP19774331.3A patent/EP3775228B1/en active Active
- 2019-03-28 CA CA3093020A patent/CA3093020A1/en active Pending
- 2019-03-28 WO PCT/US2019/024686 patent/WO2019191495A1/en not_active Ceased
- 2019-03-28 KR KR1020257018081A patent/KR20250084985A/ko active Pending
- 2019-03-28 MX MX2020009896A patent/MX2020009896A/es unknown
- 2019-03-28 JP JP2020551264A patent/JP7575271B2/ja active Active
- 2019-03-28 ES ES19774331T patent/ES3073987T3/es active Active
-
2024
- 2024-10-17 JP JP2024181460A patent/JP2025013853A/ja active Pending
-
2025
- 2025-10-24 AU AU2025256224A patent/AU2025256224A1/en active Pending